Additionally, nuclear cyclin D1 expression in GCs has been identified as an independent risk factor of GC tumour of the bone-recurrence after surgical therapy, as tumours displaying this trait have been known to be two times more recurrent than cyclin D1-negative tumours [49]. Here, CCND1 is linked to neoplasm.